iclaprim has been researched along with Health Care Associated Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corey, GR; Dryden, M; File, TM; Hadvary, P; Huang, DB; Shorr, AF; Torres, A; Wilcox, MH | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
1 review(s) available for iclaprim and Health Care Associated Infection
| Article | Year |
|---|---|
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
1 trial(s) available for iclaprim and Health Care Associated Infection
| Article | Year |
|---|---|
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Pyrimidines; Treatment Outcome; Vancomycin | 2017 |